Connect with us

Business

Cal NORML Warns of Potential THC-O Acetate Risk

Published

on

A study shows both THC-O and vitamin E acetate may convert into a dangerous lung toxin when they are heated in a vape pen.

New data shows a potential problem with vaping THC-O acetate, and the reasons are worthy of concern. The National Organization for the Reform of Marijuana Laws (NORML) branch in California, Cal NORML, issued a warning on Jan. 9 about a study that shows a significant risk for people who vape products containing THC-O acetate.

First published in the Journal of Medical Toxicology on Dec. 12, 2022, a team of researchers led by Neal L. Benowitz discovered a link between THC-O acetate and significant danger to the lungs. THC-O acetate shares structural similarities with vitamin-E acetate—an additive that becomes dangerous to the lungs when converted by heat.

According to the California Department of Public Health, the 2019-20 outbreak of EVALI lung disease sickened and hospitalized 249 Californians—five of them fatally. On Nov. 15, 2019, the Centers for Disease Control and Prevention (CDC) confirmed that vitamin E acetate is the likely culprit for EVALI. Vitamin E acetate also produces carcinogens such as alkenes and benzene when heated.

When heated in a vape pen, both substances—vitamin E acetate and THC-O Acetate—produce ketene, a “highly potent lung toxicant.”  

“We put out the press release specifically because of a study showing that vaporizing vitamin E acetate was similar to THC-O acetate,” Cal NORML Director Dale Gieringer told High Times.

 “Apparently when heated up, it produces a serious lung toxin called ketene.”

As cannabis consumers, we often have to filter through anti-cannabis hysteria, but certain risks hold weight when products aren’t regulated properly. Usually vaping dangers arise when random thickeners and unvetted compounds are added.

Gieringer added, “We have a lot of concerns about some of these other new cannabinoids that are being synthesized from hemp, which are brand new and never been tested in human subjects before. Some of them are advertised as being way more potent than THC. THC-O acetate is being advertised as three times more potent than delta-9. THCP is being advertised as having 30 times the binding power to receptors as THC. That kind of reaction sets off a lot of concerns with us. 

“These compounds have never been found in nature before—being made by fairly amateurish underground hemp chemists—raise a lot of concern.”

Gieringer added that delta-8 THC isn’t his primary concern, given there is slightly more known about the compound, but it’s contaminants and other new cannabinoids he’s most worried about, mostly due to the unknowns: THCP, THCjd. THC-H, THC-B, HHC, and Delta-10 THC. 

Cal NORML reports that the sale of psychoactive hemp derivatives was recently deemed legal under federal law by a Ninth Circuit Court decision (AK Futures v. Boyd Street Distro). That’s up for debate though, given that synthetic cannabinoids can be considered illegal under the Federal Analogue Act. 

Under the 2018 federal Farm Bill, cannabis with less that 0.3% THC is legal to grow, and its products can be sold nationally, but the THC often exceeds the limit regardless.

California’s industrial hemp law, which is overseen by the California Department of Public Health (CDPH), currently disallows the sale of hemp products with active cannabinoids other than CBD.

THC-O acetate begins as hemp-derived CBD and goes through a chemical process. Going beyond how cannabinoids like delta-8 THC are processed from CBD, acetic anhydride is added to the mixture, making it an acetate.

THC-O is believed to be three times as potent as delta-9 THC—the naturally occurring cannabinoid most of us are used to.

“Cal NORML strongly advises consumers to avoid hemp products with psychoactive cannabinoids, especially novel ones stronger than THC, whose safety is particularly suspect. CBD products may be safely obtained from state-registered industrial hemp product manufacturers, whose products must be tested for safety and cannabinoid content,” the release reads. “Under state law, hemp products should have a batch number and a label, website, QR code or barcode linking to the laboratory test results that state the levels of cannabinoids, total THC, and presence of contaminants, as well as the address and phone number of the manufacturer. Violations can be reported to CDPH.

Cal NORML adds that the less common cannabinoids that are deemed safe for human use are CBN, CBG, CBC, THCV, THC-A, CBD-A, and Delta-8 THC.

Source: https://hightimes.com/health/cal-norml-warns-of-potential-thc-o-acetate-risk/

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Business

Marijuana companies suing US attorney general in federal prohibition challenge

Published

on

Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.

According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”

Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.

The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”

The companies want the case to go before the U.S. Supreme Court.

They hired prominent law firm Boies Schiller Flexner to represent them.

The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.

Similar challenges to the federal Controlled Substances Act (CSA) have failed.

One such challenge led to a landmark Supreme Court decision in 2005.

In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.

In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.

Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.

“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.

“Moreover, the facts on which those precedents are based are no longer true.”

Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”

While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.

“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”

Source: https://mjbizdaily.com/marijuana-companies-suing-us-attorney-general-to-overturn-federal-prohibition/

Continue Reading

Business

Alabama to make another attempt Dec. 1 to award medical cannabis licenses

Published

on

Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.

The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).

Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.

Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.

That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.

Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.

Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.

A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.

Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News